GlobalGov › Germany › Pharmaceuticals › Solicitation

Germany – Pharmaceutical products – Abschluss nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Rivaroxaban (ATC-Code nach WHO: B01AF01), eingeschr. auf die Wirkstärken 10mg/15mg/20mg

Health · Germany government procurement

Closed September 30, 2026. GlobalGov surfaces government procurement from around the world, including the markets your competitors overlook.

Closed
Status

Opportunity Overview

Germany – Pharmaceutical products – Conclusion not excluding AM discount agreement pursuant to Section 130a Paragraph 8 SGB V by way of an open-house model for the active ingredient rivaroxaban (ATC code according to WHO: B01AF01), limited to the strengths 10 mg/15 mg/20 mg

Your competitors are watching the same crowded contracts everyone else is. Track live opportunities like this one worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.

Start Free

Solicitation Details

Issuing agencyHealth
CountryGermany
CategoryPharmaceuticals
PublishedAugust 19, 2025
Procurement stageActive solicitation
ClosedSeptember 30, 2026
StatusClosed — no longer accepting responses
Original languageGerman — members read it in their own language
Official sourceView original notice
Last verifiedOctober 11, 2026

Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.

Germany market overview →Pharmaceuticals tenders in Germany →Browse all categories →

Browse Similar Open Opportunities in Germany

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Posaconazol (ATC-Code nach WHO: J02AC04)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V mit dem Wirkstoff Pazopanib
Germany – Pharmaceutical products – Abschluss eines nicht exklusiven Rabattvertrages nach § 130a Abs. 8 SGB V zu Arzneimitteln mit der Wirkstoffkombination aus Emtricitabin, Rilpivirin und Tenofovirdisoproxil (ATC-Code J05AR08).
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cinnarizin und Dimenhydrinat, ATC N07CA22
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Blutzuckerteststreifen
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Alitretinoin (ATC-Code nach WHO: D11AH04)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130 a Abs. 8 SGB V zu Lösungen zur parenteralen Ernährung Kombinationen (ATC-Code: B05BA10).
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Erythropoietin zeta, ATC B03AX01

See every Germany Pharmaceuticals opportunity your competition is missing. Free for 14 days.

Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.

Start Free Trial — No Card Required

Free 14-day trial · no card required

See who is already competing here →

Get a free Germany Pharmaceuticals intelligence report in your inbox

A personalized report on Germany Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.